Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-17. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
== Pathophysiology == Dupuytren’s contracture is a fibroproliferative disorder of the palmar fascia in which abnormal activation of fibroblasts and myofibroblasts, driven by mediators such as transforming growth factor-beta, platelet-derived growth factor, epidermal growth factor, interleukin-1 beta, and connective tissue growth factor, leads to excess deposition of type III collagen and progressive remodeling of fascial tissue. Studies have suggested that intracellular signaling, as opposed to paracrine or endocrine signaling, may be the strongest driver of abnormal fibroblast activity in most cases of Dupuytren's contracture. The disease typically evolves through a proliferative stage marked by cellular nodules rich in immature fibroblasts and myofibroblasts, an involution stage in which these cells align along longitudinal stress lines in the hand, and a residual stage in which dense, relatively hypocellular collagenous cords persist and mechanically flex the digits. As normal fascial structures are converted into pathologic cords, characteristic deformities emerge: central cords commonly produce skin puckering and metacarpophalangeal contracture, natatory cords (developed from the natatory ligament) narrow the web spaces, and spiral cords can cause proximal interphalangeal contracture while displacing the digital neurovascular bundle.
=== 2009, 2011, list of genera from Tucker & Tenorio, and Bouchet et al. === This is a list of what were recognized extant genera within Conidae as per J.K. Tucker & M.J. Tenorio (2009), and Bouchet et al. (2011): However, all these genera have become synonyms of subgenera within the genus Conus as per the revision of the taxonomy of the Conidae in 2015
=== Marketing === Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the United States, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere.
Judges in Singapore were given a discretion to impose a sentence of life imprisonment with mandatory caning for offenders who commit murder but without the intention to kill, which come under Sections 300(b), 300(c) and 300(d) of the Penal Code. The death penalty remains mandatory only for murders committed with the intention to kill, which come under section 300(a) of the Penal Code. Provided that drug traffickers only act as couriers, suffer from impaired mental responsibility (e.g. depression), or substantively assist the authorities in tackling drug trafficking activities, among other conditions, judges also had the discretion to impose life sentences instead of death. Drug traffickers who were not condemned to death but to life-long incarceration with caning would receive at least 15 strokes of the cane, unless suffering from mental incapacity. Despite this discretion, a sentence of life imprisonment is the mandatory minimum penalty for capital murder or drug trafficking offences. The first person to be sentenced to life imprisonment, instead of receiving the death penalty, under the amended death penalty laws was drug trafficker Abdul Haleem bin Abdul Karim on 10 April 2013, having been a courier in traffic drugs and had assisted the authorities in disrupting the drug trafficking activities. In addition to his life sentence, Abdul Haleem, who pleaded guilty to two charges of drug trafficking, was also given the maximum sentence of 24 strokes of the cane.
Species Calotropis acia Buch.-Ham. - India Calotropis gigantea (L.) Dryand. - China, Indian Subcontinent, Southeast Asia Calotropis procera (Aiton) Dryand. - China, Indian Subcontinent, Southeast Asia, Middle East, North Africa formerly included Calotropis sussuela, synonym of Hoya imperialis
Sources: en.wikipedia.org
As relations between Washington and Moscow improved, both governments increasingly worked to restrain their respective regional allies—pressuring their former proxies to make peace with one another—and establish negotiated settlements instead, while the US concomitantly stressed market globalization. In southern Africa, Soviet and Cuban support for the Angolan government diminished as diplomacy advanced, while the United States reduced backing for anti-communist insurgents, enabling peace processes that culminated in the late 1980s. Overall, this détente which accompanied the final twilight of the Cold War would help bring about a relatively more peaceful international environment. As a consequence of the Revolutions of 1989 and the adoption of a foreign policy based on non-interference by the Soviet Union, the Warsaw Pact rapidly lost its political and military rationale and began to dissolve. Meanwhile, troops stationed across eastern Europe began returning to the Soviet Union, completing their withdrawal by the mid-1990s. This marked the end of the Soviet military presence that had defined the political order in Europe since 1945. For all the complexity and geopolitical strain that the great power competition of the Cold War brought onto Europe during the second half of the 20th century, its trajectory turned out to be both "more prosperous and peaceful for Europeans than the first," so quips German historian Konrad Jarausch.
During his second presidency, Donald Trump launched a campaign of anti-LGBTQ+ and especially anti-transgender policies that eliminated federal recognition of transgender people, stripped legal protections, and sought to erase trans identities from public life. Through a series of executive orders, the administration defined sex strictly by birth biology, banned trans people from the military, restricted or defunded gender-affirming healthcare, censored research and education materials, and targeted schools, universities, and cultural institutions accused of promoting "gender ideology". Additional measures barred transgender athletes from sports, limited passport access, and fueled international efforts to undermine trans rights. Accompanied by rhetoric portraying transgender people as a societal threat, these policies triggered widespread legal challenges, condemnation from human rights groups, and a surge in emigration and asylum claims by transgender Americans.
Keith G. Harding CBE FRCGP FRCP FRCS FLSW is a British physician. Harding graduated from Birmingham University with an MBChB degree in Medicine in 1976. Harding is the Director of TIME Institute (Translation, Innovation, Methodology and Engagement) and Head of the Wound Healing Research Unit in the School of Medicine at Cardiff University. He is Clinical Lead for Wound Healing in the Cardiff & Vale NHS Trust. In September 2013 Harding was appointed Dean of Clinical Innovation at Cardiff University. From 2002 to 2005 he was Head of the Department of Surgery at Cardiff University. He is Editor-in-Chief of the International Wound Journal. Keith Harding is a Past President of the European Tissue Repair Society. He was the first President of the European Pressure Ulcer Advisory Panel, and first Recorder of the European Wound Management Association. Harding was Chair of the International Working Group on Wound Healing in Diabetic Foot Disease in 2003. He was Chair of the Expert Working Group that produced a range of International Consensus Documents from 2004 to 2011. Professor Harding was appointed a Commander of the Order of the British Empire in the 2013 New Year Honours for services to medicine and healthcare. Harding is a Fellow of the Royal College of General Practitioners, a Fellow of the Royal College of Physicians, and a Fellow of the Royal College of Surgeons. In 2014, Professor Harding was elected a Fellow of the Learned Society of Wales.
=== Aftermarket TPMS === Aftermarket TPMS systems are designed to be retrofitted to vehicles that were not originally equipped with the technology. These systems are available for a wide range of vehicles, from bicycles and trailers to heavy-duty trucks. In commercial fleets, aftermarket TPMS are used as part of fleet digitalization. The sensors on each tire wirelessly transmit real-time pressure and temperature data to a GPS tracking unit in the vehicle. This data is then relayed to a fleet management software platform, allowing fleet managers to remotely monitor tire health, receive alerts for under-inflation, and help prevent blowouts or excessive fuel consumption.
==== Film and television ==== Cartoon Network, the Disney Channel, and Nickelodeon were once staples of children's entertainment among Millennials and Generation Z. But viewership began to drop in the early 2010s. Nielsen figures for 2020 revealed that the viewership of children's cable linear television channels continued their steady decline despite the COVID-19 pandemic, which forced many parents and their children to stay at home, while streaming services saw healthy growth. Among members of Generation Z who regularly watch movies, demand for physical media (DVDs and Blu-rays), both for sale and for rent, has been climbing in the 2020s. Animations, including those made in Japan (known as anime), are in high demand among Generation Z. By the mid-2020s, the most popular television series among Generation Z include My Hero Academia (2016–present), Steven Universe (2013–2019), Invincible (2021–present), Euphoria (2019–2026), Star Wars: The Clone Wars (2008–2020), and Loki (2021–2023). Generations Z and Alpha also enjoy comfort television shows popular with older cohorts or ended before they were born, such as Friends (1994–2004) and Gilmore Girls (2000–2007; 2016), as well as shows featuring characters roughly their age, like Young Sheldon (2017–2024) and Stranger Things (2016–2025), and long-running television drama, like Grey's Anatomy (2005–present). The Netflix science-fiction horror series Stranger Things became a popular TV series to Generation Z by using and evoking nostalgia for the 1980s.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.